

# **Key Investor Information**

This document provides you with key investor information about this fund. It is not marketing material. The information is required by law to help you understand the nature and the risks of investing in this fund. You are advised to read it so you can make an informed decision about whether to invest.

### UBS (Lux) Equity Fund - Biotech, class (USD) P-acc (ISIN: LU0069152568), USD

a sub-fund of UBS (Lux) Equity Fund

This fund is managed by UBS Fund Management (Luxembourg) S.A., a part of UBS AG.

### **Objectives and investment policy**

The fund assets are largely invested in stocks related to the biotechnology sector. The fund's investments are selected from all countries, and the fund's positions are very actively managed.

The portfolio manager allocates the assets according to a thorough investment process based on fundamental research. The stock selection is based on the assessment of the opportunities associated with the respective risks. It is possible that fund assets could temporarily be concentrated in particular areas.

Investors may demand to redeem their units from the investment company on any normal bank business day.

Fund income is not paid out, but instead will be reinvested.

### **Risk and reward profile**

Lower	risk			Higher risk		
Typically lower rewards			Typically higher rewards			
1	2	3	4	5	6	7

### More about the risk category

- The risk category is based on the fund's return volatility over the last five years. If the fund has less than 5 years' history, estimated volatility is used for the missing period.
- The fund is in category 6 because the volatility of its past returns has been very high.
- Historical data may not be a reliable indication for the future.
- The risk category shown is not guaranteed and may vary over time.
- The lowest risk category does not mean 'risk free'.

Recommendation: this fund may not be appropriate for investors who plan to withdraw their money within five years.

### Further material risks

- No capital guarantee exists for this product, so investors could lose the whole of their investment.
- A portion of the fund is invested in less liquid investments where bid-ask spreads and the price impact of trading might increase significantly under adverse market conditions.

## ල්ලි UBC Charges

The charges you pay are used to pay the costs of running the fund, including the costs of marketing and distributing it. These charges reduce the potential growth of your investment.

One-off	charges	taken	before	or	after	vou	invest	
one on	churges	unchi	DCIDIC	01	uncer	you	nivest	


5	,	
Entry charge		6.00%
Exit charge		2.00%
Conversion charge		3.00%

This is the maximum that might be taken out of your money before it is invested / before the proceeds of your investment are paid out.

Charges taken from the fund over a year			
Ongoing charges	2.17%		
Charges taken from the fund under certain specific conditions			

Performance fee none

Past performance



The entry charge and exit charge shown are maximum figures. In some cases you might pay less – you can find this out from your financial adviser.

The ongoing charges figure is based on expenses for the year ending in 2011. This figure may vary from year to year. It generally excludes:

• Portfolio transaction costs, except in the case of an entry/exit charge paid by the fund when buying or selling units in another collective investment undertaking.

For more information, please see the charges section of the fund's prospectus, which is available at www.ubs.com/ funds.

# Performance in the past is not a reliable indicator of future results.

The chart shows the class's investment returns calculated as a percentage year-end over year-end change in the fund's net asset value. In general, any past performance takes account of all ongoing charges but not the entry charge. If the fund is managed against a benchmark, its return is also shown.

The class was launched in 1996. The past performance is calculated in USD.

### **Practical information**

### Depositary

UBS (Luxembourg) S.A.

### **Further Information**

Information about the UBS (Lux) Equity Fund and its available share classes, the full prospectus and the latest annual and semi-annual reports can be obtained free of charge in English and German from the representative or online at www.ubs. com/funds. Other documents are also available.

The representative in Switzerland is UBS Fund Management (Switzerland) AG, Brunngässlein 12, 4002 Basel. The paying agent in Switzerland is UBS AG, Aeschenvorstadt 1, 4002 Basel and Bahnhofstr. 45, 8098 Zurich.

The currency of the unit class is USD. The price of shares is published on each business day and are available online at www.ubs.com/funds.

Existing investors may switch between sub-funds of the umbrella and/or classes at the conversion charge indicated above.

### **Tax Legislation**

The laws and regulations of your country of residence might have an impact on your investment. For further details you should consult a tax adviser.

### Liability Statement

UBS Fund Management (Luxembourg) S.A. may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the prospectus.

This fund is authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier (CSSF). UBS Fund Management (Luxembourg) S.A. is authorised in Luxembourg and regulated by the supervisory authority Commission de Surveillance du Secteur Financier (CSSF). This key investor information is accurate as at 27/01/2012.